Abstract: The computing-in-memory circuit includes: an SRAM memory cell array including at least one memory cell connected between a first bit line and a second bit line, the memory cell includes a first inverter and a second inverter cross-coupled with each other, and the first inverter and the second inverter have an asymmetric configuration with respect to each other; a control circuit configured to: receive a first input signal, a second input signal and an operation mode control signal, process the first input signal and the second input signal according to operation mode control signal, so as to obtain a processed first input signal and a processed second input signal, and apply the processed first input signal and the processed second input signal to the first bit line and the second bit line, respectively; and a readout circuit configured to read out data stored in memory cell from the memory cell.

Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof, contains an imidazole, or is miconazole or a salt thereof.

Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.

Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.